Skip to main content

Bio-Rad Laboratories, Inc. (BIO)

NYSE: BIO · IEX Real-Time Price · USD
721.48 1.37 (0.19%)
Oct 15, 2021 4:00 PM EDT - Market closed
Market Cap21.58B
Revenue (ttm)2.88B
Net Income (ttm)4.05B
Shares Out29.76M
EPS (ttm)134.05
PE Ratio5.38
Forward PE50.51
Dividendn/a
Ex-Dividend Daten/a
Volume100,900
Open720.08
Previous Close720.11
Day's Range713.22 - 725.47
52-Week Range507.22 - 832.70
Beta0.89
AnalystsBuy
Price Target856.25 (+18.7%)
Est. Earnings DateOct 28, 2021

About BIO

Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research tech...

IndustryLife Sciences Tools & Services
Founded1952
CEONorman Schwartz
Employees7,700
Stock ExchangeNYSE
Ticker SymbolBIO
Full Company Profile

Financial Performance

In 2020, BIO's revenue was $2.55 billion, an increase of 10.12% compared to the previous year's $2.31 billion. Earnings were $3.81 billion, an increase of 116.43%.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for BIO stock is "Buy." The 12-month stock price forecast is 856.25, which is an increase of 18.68% from the latest price.

Price Target
$856.25
(18.68% upside)
Analyst Consensus: Buy

News

Bio-Rad to Report Third-Quarter 2021 Financial Results, Thursday, October 28, 2021

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the third...

23 hours ago - Business Wire

Bio Rad (BIO) Global Growth Strong, Expenses Continue to Rise

Bio Rad (BIO) is witnessing strong growth in the biopharma market, riding on the Droplet Digital PCR platform.

2 weeks ago - Zacks Investment Research

A Trio of Stocks for Growth-Oriented Investors

Growth-oriented investors may want to consider the following stocks since they represent businesses with price-earnings ratios below 20 and recorded significant improvements in trailing 12-month earning...

Other symbols:BLDRFCX
4 weeks ago - GuruFocus

Bio-Rad (BIO) Upgraded to Strong Buy: Here's Why

Bio-Rad (BIO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

4 weeks ago - Zacks Investment Research

Bio-Rad Laboratories (BIO) Is Up 0.05% in One Week: What You Should Know

Does Bio-Rad Laboratories (BIO) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 month ago - Zacks Investment Research

Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio Now

Investors are optimistic about Bio-Rad (BIO) on solid international market performance and raised 2021 guidance.

1 month ago - Zacks Investment Research

What Makes Bio-Rad (BIO) a Good Fit for "Trend Investing"

Bio-Rad (BIO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

1 month ago - Zacks Investment Research

Bio-Rad to Participate in the 2021 Virtual Wells Fargo Healthcare Conference

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that management will partic...

1 month ago - Business Wire

New Analyst Coverage Puts Spotlight on These 5 Stocks

Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like NBTB, BIO, RDNT, ABR and CATY.

Other symbols:ABRCATYNBTBRDNT
1 month ago - Zacks Investment Research

This Unknown Biotech Has a Secret Weapon for Outsized Returns

Bio-Rad's equity position in a German pharma company is an asset many investors may not realize.

Other symbols:CGENTMO
1 month ago - The Motley Fool

5 Stocks With Recent Price Strength Amid Robust Reopening

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength like VRTV, LCUT, GRIN, CMRE and BIO have a high chance of carrying the momentum forward.

Other symbols:CMREGRINLCUTVRTV
1 month ago - Zacks Investment Research

Bio-Rad (BIO) Hits a New 52-Week High: What's Driving It?

Strong performance across the Life Science and Clinical Diagnostics businesses drove the top line for Bio-Rad (BIO).

1 month ago - Zacks Investment Research

5 Stocks to Buy as Analysts Initiate Coverage

Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like CATY, BIO, CHE, MTLS and ABR.

Other symbols:ABRCATYCHEMTLS
2 months ago - Zacks Investment Research

Bio-Rad Laboratories: Surging Growth Continues

Bio-Rad Laboratories, Inc. ( BIO , Financial) is maintaining the torrid rate of growth that has made it one of the most exceptional performers of the past half-decade. This year, the life science resear...

2 months ago - GuruFocus

Surging Earnings Estimates Signal Upside for Bio-Rad (BIO) Stock

Bio-Rad (BIO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Other symbols:RAD
2 months ago - Zacks Investment Research

Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio

Investors are optimistic about Bio-Rad (BIO) backed by strong segmental performance across geographies in the second quarter and raised 2021 guidance.

2 months ago - Zacks Investment Research

What Makes Bio-Rad (BIO) a Good Fit for "Trend Investing"

Bio-Rad (BIO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

2 months ago - Zacks Investment Research

Bio-Rad (BIO) Q2 Earnings Top Estimates, 2021 View Raised

Strength in Life Science and Clinical Diagnostics segments during the second quarter drove Bio-Rad (BIO) revenues.

2 months ago - Zacks Investment Research

Bio-Rad Laboratories (BIO) Q2 Earnings and Revenues Beat Estimates

Bio-Rad (BIO) delivered earnings and revenue surprises of 86.32% and 17.29%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Bio-Rad Reports Second-Quarter 2021 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the s...

2 months ago - Business Wire

Bio-Rad and 10x Genomics Announce Settlement to Resolve Multiple Litigations

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Bio-Rad and 10x Genomi...

2 months ago - Business Wire

Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?

Improvement in demand at non-COVID business and continued strength in Bio-Rad's (BIO) Life Science segment are likely to have contributed to Q2 results.

2 months ago - Zacks Investment Research

Bio-Rad Laboratories (BIO) Earnings Expected to Grow: Should You Buy?

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

What's Next For Bio-Rad Laboratories Stock After A 10% Rise In A Month?

The stock price of Bio-Rad Laboratories, a life science research and clinical diagnostic products company, has seen a 10% rise over the last twenty-one trading days, while it is up 30% over the last yea...

Other symbols:RAD
2 months ago - Forbes

Bio-Rad to Report Second-Quarter 2021 Financial Results, Thursday, July 29, 2021

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the secon...

3 months ago - Business Wire